Basal insulin and cardiovascular and other outcomes in dysglycemia

Keyphrases

• Dysglycemia 100%
• Insulin Glargine 100%
• Basal Insulin 100%
• Confidence Interval 66%
• Hazard Ratio 50%
• Fasting Plasma Glucose 50%
• Diabetes 33%
• Care Groups 33%
• Cardiovascular Outcomes 33%
• Hypoglycemia 33%
• Cardiovascular Risk 16%
• In Cancer 16%
• No Significant Difference 16%
• Between-group 16%
• Placebo 16%
• Type 2 Diabetes Mellitus (T2DM) 16%
• Odds Ratio 16%
• New-onset Diabetes 16%
• Revascularization 16%
• Impaired Fasting Glucose 16%
• 2-factorial Design 16%
• Cardiovascular Events 16%
• Heart Failure Hospitalization 16%
• Vascular Outcomes 16%
• Nonfatal Myocardial Infarction 16%
• Nonfatal Stroke 16%
• Impaired Glucose Tolerance 16%
• Incident Cancer 16%
• Cancer Hazard 16%
• Neutral Effects 16%
• Incident Diabetes 16%
• Severe Hypoglycemia 16%
• 3 Fatty Acids 16%

Medicine and Dentistry

• Cardiovascular System 100%
• Insulin Glargine 100%
• Dysglycemia 100%
• Diabetes 66%
• Hazard Ratio 50%
• Malignant Neoplasm 50%
• Hypoglycemia 50%
• Care Group 33%
• Apoplexy 16%
• Congestive Heart Failure 16%
• Maturity Onset Diabetes of the Young 16%
• Myocardial Infarction 16%
• Placebo 16%
• Cardiovascular Risk 16%
• Blood Glucose 16%
• Revascularization 16%
• Impaired Glucose Tolerance 16%
• Impaired Fasting Glucose 16%
• Omega-3 Fatty Acid 16%
• Odds Ratio 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Dysglycemia 100%
• Insulin Glargine 100%
• Malignant Neoplasm 50%
• Hypoglycemia 50%
• Heart Infarction 16%
• Congestive Heart Failure 16%
• Placebo 16%
• Cardiovascular Risk 16%
• Cerebrovascular Accident 16%
• Omega-3 Fatty Acid 16%
• Impaired Glucose Tolerance 16%
• Non Insulin Dependent Diabetes Mellitus 16%